Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 Oct. 6];7(2):s114. Available from: https://skin.dermsquared.com/skin/article/view/1964